alywoah
5,000+ Views

Big Quad Problems...

Well thank god for dresses!

24 Comments
Suggested
Recent
@marshalledgar Well personally, I rather fit into jeans than have huge ass quads. Gotta get the fashion game strong as well!
I might have huge pecs, but even when I squat like crazy, my legs never get huge.
lol @ marshalledgar I'm right there with you.. like @alywoah I've learned jeggings/leggings for the win I remember telling my bro's gf the other day I needed to go outside to do yard work but I was too lazy to change my pants after all the work it took to get in them :-P
you can have quads it skinny jeans, never both. I'm wearing boot cut jeans rn, and I have some big quads
I like gymshark's leggings.... Leggings plus bball shorts @alywoah
Cards you may also be interested in
What COVID-19 Impacted on Blood Lancet in Healthcare Industry ?
Impact of COVID-19 on Blood Lancet in Healthcare Industry The first case of the COVID-19 pandemic was found in Wuhan, China. This pandemic has influenced the whole planet with its significant impacts on the economy and businesses worldwide. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature. As a result, the most outstanding medical challenge in the 21st century is yet to face physicians worldwide. Though the emergence of the virus can be tracked back to Asia, many European countries and the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East and Africa up to South America. The COVID- 19 has been declared a pandemic by World Health Organization (WHO) due to its increased spread globally. After the pandemic declaration, various countries announced the complete lockdown such as the Russia, Europe and Asian countries, to decrease its spread. Regardless of the pandemic of COVID-19, the demand for blood lancets has increased in healthcare applications. Blood lancets are scalpel-type medical instruments with a double-edged blade used for various diseases for blood diagnosis procedures in hospitals, clinics and the home healthcare arena. According to the situation report of 11th May 2021 by World Health Organization (WHO) stated 157 million cases of coronavirus patients had been reported globally and 3.3 million patients are dead due to the coronavirus. America is leading in cumulative cases with a record of 64 million and 1.5 million death rates. At the same time, nearly 1.45 billion doses of COVID-19 vaccines have been administered globally. The outbreak of COVID-19 has a significant impact on the healthcare and supply chain of various medical devices and kits, including blood lancets. IMPACT ON DEMAND The COVID-19 pandemic has lifted the blood lancet market from its niche pedestal to the mainstream sector. However, even before the pandemic, blood lancets' demand was highly interested in rising chronic diseases such as diabetes, hyperlipidemia and more. For instance, · As per World Health Organization's (WHO) report released on 13th April 2021, the diabetes cases raised from 108 million to 422 million from 1980 to 2014, specifically higher in middle and low-income countries. · In 2019, 1.5 million death rates were directly estimated for diabetes. The rising research and technologies in the medical sector have made various types of blood lancets invade specific applications. These lancets are disposable, which surges its application for pain-free and safe blood diagnosis. This also minimizes the risk of blood transfusion and infection transmissions. The coronavirus pandemic has further increased the demand for blood lancets since COVID-19 can also be diagnosed using a blood test. For instance, · As per the 14th September 2020 published report of the U.K. Government, their coronavirus antibody test kits are delivered home for simple blood sample tests. The limited amount of blood can be drawn using finger-prick disposable blood lancets and provided to labs for 3-7 days results. In the current scenario, coronavirus's rising transmission rate has made homecare and self-diagnosis kits and procedures highly prevailing in the market. Due to its disposable nature, painless and easy usability blood lancets are highly preferred by healthcare professionals in chronic infection diagnosis. Several companies operating in other domains are eager to enter. Some have already entered the landscape of the blood lancet market to increase their revenue by meeting the emergent need of diagnosis kits and blood tests for the virus infection. The demand is further rising in local clinics and small laboratories for blood sugar and lipid testing. Furthermore, the coronavirus lockdown and lack of hospital admissions for other chronic diseases as diabetes have boosted self-monitoring diagnostic procedures among patients. Since blood lancets an ideal device for self-diagnosis, this has increased the market demand to a greater extend. The rising geriatric population and obese individuals, because of unsanitary food habits and lack of physical exercise, have increased chronic illness cases as diabetes on hype. The life-threatening diseases are compelled to be maintained and treated often, which raises the diagnosis requirements globally. Therefore, the affirmative factors boost the demand for blood lancets among patients. PRICE IMPACT The COVID-19 had a devastating impact on the global economy. The several establishments have to remain shut while others scale down the operations or put on hold expansion plans as they tried to survive the unprecedented crisis. However, the demand for blood lancets has been rising because of the increasing prevalence of diabetes patients and their routine self-care diagnostic management. Despite lockdowns and supply disruption crises during this pandemic, the companies manage online sales and delivery of blood lancets without the mandatory requirement of prescriptions. They are also maintaining fair prices owing to the high demand for blood lancets in the market. For instance, · Ever Ready First aid twist cap blood lancets of 500 counts per package costs USD 10.00, which is delivered home with high safety precautions. · Apollo Pharmacy provides home delivery for blood lancets conveniently considering the product under the counter category. The COVID-19 impact has not affected the price of blood lancets at a high level because of advanced online sales and innovative delivery options available with the utmost safety concerns. IMPACT ON SUPPLY CHAIN The COVID-19 has created a significant impact on the supply chain of the blood lancet market. The sudden attack of COVID-19 and its subsequent implications for restrictions on trade and movement of goods has resulted in a shutdown of vast countries globally, resulting in disrupted supply chains due to limited materials and workforce and slow down or stopping of manufacturing. Moreover, several manufacturing companies are retooling priority manufacturing to produce other essential medical supplies and equipment such as ventilators. But since the blood lancets are in high demand by various healthcare sectors, the supply chain is again gaining speed due to an increase in order from the consumers. The government allows the moments of transport vehicles to import and export the raw materials to produce lancets. Additionally, the manufacturers are also taking crucial steps to ensure the availability of raw materials by and also they have to look into the quality of products. Therefore, manufacturers need to take necessary steps about production processes, shifting to other facilities if required, changes in quality assurance, costs and procedures related to screening workforce and offering of care if needed, changes in working hours and others to maintain their supply chain. To minimize supply chain crises, the government has been firmly monitoring the supply chain to assume that the COVID-19 outbreak may adversely impact the supply chain of a medical product, including shortages of blood lancets for various healthcare sectors countries globally or potential disruptions in supply chains. To manage such a crucial situation, many organizations are looking forward to improving and diversifying the supply chain model in all aspects. For instance, · Roche Diabetes Care has taken initiatives for uninterrupted Accu-Chek diabetes test kits and lancet products supply during this health crisis of COVID-19 lockdowns. They are supplying homes with their diabetes self-management lancets and lancing devices with online booking and free delivery without the requirement of prescriptions. · They have also reported that the COVID-19 pandemic has not impacted their supply because of the robust manufacturing facility and evolving solutions. The resulting COVID-19 pandemic has shown the various ways for supply chain management, which may be effective by innovative solutions initiated by the market players. CONCLUSION The impact of the novel COVID-19 virus is expected to leave a long-lasting effect on each healthcare sector. The outbreak of COVID-19 prompted citizens to deal with confusion regarding the virus and its management. The virus poses a risk to human life and has caused economic distress and severe emotional strain. In addition, it produced a ripple effect that gave rise to a new collection of requirements and needs that were not much needed earlier and the essential one being the blood lancets which is highly required in hospitals, clinics, labs and home healthcare setups. It is estimated that the COVID-19 pandemic outbreak was having a positive impact on the growth of the blood lancet market owing to the requirement of self-diagnosis and management by numerous diabetic patients worldwide. Moreover, many international governments, including the U.S, Europe and Asia's healthcare organizations, have supported the supply of blood lancets and other diagnostic kits in the medical and home healthcare arena due to high priority and essential requirements for a crucial health crisis period. Many government bodies and significant market players are closely associated with chronic patients and healthcare professionals for better home care and self-diagnosis, considering the contagious nature of the virus and improvement of future economics with disposable blood lancets.
Cool Shit You Should Know About Squatting
Squatting is one of the most important lifts you'll ever learn. It's a compound movement that targets several areas of your body (not just the booty). Actually, depending on the variation of squat used, you might be targeting of your quads, hamstrings, or glutes more over the other groups. My favorite type of squat is the high-bar squat, which means the bar is placed higher on your back, sitting right on your traps. It's really great for quad strength, as well. Tryyyy it. Here's some cool shit about squatting ;) 1 - It'll Make You Feel Powerful Especially when the lift is performed correctly. Believe me, it's more impressive to execute the lift correctly with perfect form and lower weight, than to wobble and buckle with heavy-ass-weight. Either way, when you feel that bar hug against your back, and you feel your legs burn, you'll feel that instant power. 2 - Squats help build muscle throughout your body It's not just your booty getting the gains, it's other parts too. Since this is a compound movement, it promotes muscle growth for other parts, as well. Squats especially help out with your calves, glutes, hamstrings, quads, and core. 3 - You don't need a barbell for squat gains Look, you don't need a barbell for this exercise.There are so so many ways you can execute a squat. It can be with dumbells, kettlebells, sand bags, or even your dog/child. Want to do some intense body-weight squats?Check out THIS CARD to read about explosive jump squats. 4 - It's actually a natural movement When you think about it, a lot of squat throughout the day during our normal daily routines. It can be from squatting down to pick something up, or rising from a chair. In other cultures, you might even find people squatting to eat a meal. Squats are bad for your knees? Nah, not squatting is bad for your knees. ;) 5 - Tired of ineffective sit ups? Try squatting. When squatting, you should focus on also engaging your core. The muscles in both your mid-section and your lower back are utilized for balance and control over the movement. When you are squatting, think about activating that core. Exercises like sprinting, deadlifting, and squatting, will be far more better for fat burning and building core muscles than your half-ass sit-ups.
(no title)
ラブドールをトラックの助手席に座らせて運ばせる客 そのうえ、新藤さんは緊急事態宣言下の今年春ごろ、とんでもない“荷物”の引越しもさせられている。その荷物とは、人間と見紛うほどリアルなラブドールである。 いったいどういう状況でラブドールを運ぶことになったんですか 新藤 その客は古い2DKのマンションに住む30代前半の小柄な男性で、一見すると物静かな印象でした。荷物の量自体は普通のひとり暮らしの男性と同じだったんですが、奥の3畳ほどの部屋だけは、なぜかガラス戸が固く閉まったままでした。そこでガラス戸を開けると、アンティーク風の椅子が真ん中にあり、髪が長くて肌の白い人形がフェミニンな服を着て座っていたんです。ものすごく高品質かつリアルなダッチワイフで、最初は人間の女性に見えました。作業員が集まって「あれはなんだ」「人?」「いや人形じゃないか」とヒソヒソ相談したくらいです。 ─たしかに最近のラブドールのクオリティはすごいと聞きます。 新藤 でも、大変だったのはそこからでした。通常の手順通り、セックス人形にプチプチを巻いて緩衝材の布をかけようとしたら、男性が血相を変えて「何をしているんですか!!」と僕の手をガッとつかんだんです。「梱包して運ぼうとしているんですが」と答えると、男性は「それは違うでしょ。普通は人にそんなことをしない」と真剣な表情で言う。なるほど。男性にとってそのラブドールドールは「人」であり「彼女」なんですね。 https://www.saikodoll.com/ セックス人形と並んで座り新居まで 新藤 そういうことみたいです。それで先輩を交えて男性と相談した結果、トラックの座席にドールを乗せて移動することになりました。通常の作業時は運転手、先輩、僕の3人で座席に乗って移動するんですが、僕は機材を運搬する別の車両に乗り、代わりにセックス人形を助手席に座らせて、ちゃんと人間のようにシートベルトも着用させて運びました。 先輩はめちゃくちゃ恥ずかしかったそうです。新居までの移動時間が1時間あまり。その間、作業着姿のおじさん2人がラブドールと並んで座り、ほかのドライバーからジロジロ見られ続けたわけですから。そういう意味では、この男性は本当に迷惑な客でした。
High Healthcare Expenditure To Drive The Growth Of The Operating Room Management Market
The pandemic has led to a temporary ban on elective surgeries across the globe, which resulted in cancellations of elective surgeries worldwide. According to a report published by researchers of CovidSurg Collaborative, around 28 million surgeries were canceled across the globe during 12 weeks of peak disruption during the COVID-19 pandemic.   To handle the increased surgical volumes, hospitals are increasing OR hours and focusing on better utilization of OR. The COVID-19 will positively impact the ORM software market. It will increase the adoption rate of ORM software as most hospitals will now focus on increasing capacity by using technology to improve efficiency.  The overall cost of healthcare delivery has grown significantly over the last few decades, mainly due to increasing health insurance premiums, the rising demand for quality healthcare services, the rising geriatric population, and the increasing incidence of chronic disorders.  Another important factor attributing to rising healthcare costs is the high dependency on traditional and outdated methods such as paper-based patient records, which leads to an increase in readmission rates, medical errors, and administration costs.  Different governments and healthcare systems worldwide are now focusing on controlling rising healthcare costs by minimizing patient readmissions, medical errors, and administration costs with the effective utilization of various healthcare IT solutions. Operating rooms or ORs account for 40% of the total hospital expenses and constitute ~70% of the total revenue generated.   For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=175407912 The adoption of ORM solutions has been particularly affected by its high installation and maintenance costs. ORM software, when once installed, also requires to be regularly updated as per the user’s requirement and software enhancements, thereby presenting recurring expenditure. Additionally, the maintenance of high-end IT-enabled systems typically costs more than the software itself.  The annual maintenance cost is estimated to be 20-25% of the initial cost of the software licenses. Subsequently, it can be expected that the high costs incurred from the purchase, installation, maintenance, and upgrade of ORM software and solutions may negatively affect their overall adoption among end-users, thus restraining market growth to a certain extent.  Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. According to the World Economic Forum, these emerging economies will account for around one-third of the global healthcare expenditure by 2020. More than half of the world’s population resides in India and China, owing to which these countries are home to a large patient base. The increasing burden of cancer, improvements in healthcare infrastructure, a less-stringent regulatory environment, and growing medical tourism are encouraging players in the operating room management market to increase their presence in emerging countries. Owing to the expansion of the patient population base, the number of hospitals and surgical centers is also expected to increase in emerging countries in the coming years. Also, currently, governments in these countries are undertaking initiatives to expand and modernize their respective healthcare infrastructures.  The number of independent health care providers has been decreasing as most healthcare providers are turning to mergers, acquisitions, and partnerships and are functioning under a health system rather than operating independently. On a 15-year basis, the percentage of hospitals functioning under a health system has increased from approximately 50% to approximately 65%. Today, over 70% of hospitals are operating as part of a health system rather than independently.  Data management communication solutions accounted for the largest share of the operating room management market in 2019 owing to the benefits such as easy sharing of patient status in perioperative care phases, tracking of the schedule compliance, and sharing of the media and information related to cases within different operating rooms or external hospital departments.  The high growth of this segment can primarily be attributed to advantages such as scalable data storage, scalable computing power, machine-learning capabilities, and faster data transfer between organizations of cloud platforms.
Cell Counting Market - Trends, Growth and Future Analysis
The market growth is largely driven by factors such as growing funding for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematology analyzers. On the other hand, the high cost of cell analysis is expected to hinder market growth to a certain extent.  The medical application segment will grow at the highest CAGR in the cell counting market. Increasing government initiatives in stem cell research and the wide usage of cell counting in research are the major factors driving the growth of the research applications segment during the forecast period.  The high growth of this segment can primarily be attributed to the growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical RD expenditure, and commercial expansion of various pharmaceutical companies.  For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157450728 The large growth of this segment can be attributed to factors such as the growing number of proteomics, genomics, and stem cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization.  The major companies in the cell counting market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), and Bio-Rad Laboratories (US). 
The Importance of Bioprocess Containers - Research News
The growth of single-use technologies can be attributed to the growing need for better, cheaper, and faster biologics production. Active development of individualized biologics and personalized medicines, including patient-specific cellular gene therapies and therapeutic vaccines, demands high sterility and is therefore manufactured using single-use equipment and consumables.   In recent years, more biologics having higher potency that require smaller production volumes, advancements in biosimilars targeting smaller markets, and ongoing improvements in production yields and efficiencies that create production operations at much smaller scales have increased the use of single-use technologies such as single-use bioprocess containers/bags as they are best suited for small volume productions. However, single-use technologies are now slowly moving towards clinical production and commercial operations. In 2020, the US FDA approved 53 new medicines and therapeutic biologics (Source: US FDA). Growth in the biologics market is mainly driven by monoclonal antibodies and human insulin, which are among the leading contributors to the bioprocess containers market. Additionally, the Centre for Biologics Evaluation and Research’s (CBER) (2021-25) strategic plan involves various schemes for boosting the growth of the biologics market.  Compared to traditional bio-manufacturing technologies, single-use systems (SUS) have many advantages, such as reduced requirements for process validation and higher manufacturing flexibility, which ultimately results in higher operating efficiency and reduced manufacturing costs.  Despite these advantages, there is a possibility that the plastic materials used for SUS may leach organic compounds or inorganic substances into the processing fluid or the final drug product, which remains a major concern. Such an undesired change could eventually compromise bioprocessing and might significantly impact the safety, quality, and purity of the drug product.   For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107645832 According to a survey conducted by BioPlan Associates in 2018, 73.3% of respondents agreed that leachables and extractables are major concerns that may limit the use of bioprocessing in the near future. As single-use assembly products are made of processed plastic materials, they often face the problem of contamination from the container due to leachables.  The patent expiry of blockbuster drugs has resulted in increased RD spending by pharmaceutical and biotechnology companies. Patent expiry of biologics leads to increasing RD of biologics and shifts biologics from the pipeline to commercial production. As the development and manufacturing costs of biologics are very high, companies are now gradually focusing on techniques that are more economical than traditional biomanufacturing methods.   Most single-use assemblies are made of multiple materials or layers, including polyethylene, polypropylene, ethylene vinyl alcohol, or nylon. Such products require extensive efforts to separate components into homogeneous components. As a result, most single-use assemblies and their components are not suited for recycling. This leads to the generation of large volumes of solid waste; its disposal is a challenging prospect for biopharmaceutical companies.  Recent Developments In June 2021, Avantor, Inc. (US) acquired RIM Bio, a leading China-based manufacturer of single-use bioprocess bags and assemblies for biopharmaceutical manufacturing applications. This acquisition helped the company expand its bioproduction footprint in China. In April 2021, Sartorius Stedim Biotech (France) opened a new Customer Interaction Center (CIC) in Beijing, China, to expand its presence in China and to meet the high demand from the growing biopharmaceuticals market. In March 2021, Merck KGaA (Germany) invested ~USD 30 million (EUR 25 million) to add a single-use assembly production unit at its Life Science Center in Molsheim, France. With this expansion, the company is accelerating its European expansion plans for single-use technology, which is used for the production of COVID-19 vaccines and other lifesaving therapies.  Key Market Players The bioprocess containers market is dominated by a few globally established players such as Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation (US), and Merck Millipore (Germany)
Real World Evidence Are Used To Monitor The Post Market Safety and Adverse Events of Drugs
The emergence of this pandemic has posed severe financial constraints on pharma-biopharma companies in several countries. In this regard, RWE solutions have proven to be very helpful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while helping to organize and evaluate clinical data for regulatory submissions. The uncertainty brought on by the COVID-19 pandemic has dramatically shifted how and when patients decide to seek medical care. In addition, shifts in healthcare coverage and provision during the pandemic have changed the discovery and reporting of certain outcomes in data and the treated population. This means that disease trends may lead to incorrect interpretations when RWD and RWE are not framed in the context of the pandemic and long-term COVID-19 disease, therapy, and lifestyle changes.   RWE is set to become the most influential emerging technology to help in the fight against the COVID-19 outbreak, according to the latest poll on GlobalData’s Pharmaceutical Technology website. In this poll, which was completed by 935 of its readers in April 2021, more than one-third of the respondents indicated that RWE would have the greatest impact on the management of COVID-19.  Even though emerging technologies, such as telemedicine, have existed for decades, most of healthcare systems rely heavily on in-person interactions between patients and clinicians. Nevertheless, the current requirement for social distancing measures is swiftly pushing the primary care provision toward remote care. Telemedicine and virtual care may also prompt a greater adoption of technologies such as wearables and digital therapeutics, thus accelerating digitalization in the healthcare space and boosting the importance of RWE and AI.  Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991 The utilization of RWE in infectious disease control is not a new concept. During the Ebola outbreak in 2014, forecasters successfully used Global Epidemic and Mobility (GLEaM) simulations that combined real-world data on populations and their mobility with rigorous stochastic models of disease transmission to predict the global spread of the disease.  In countries with strict data privacy laws, the implications of contact-tracing apps on individual privacy are considered a major associated concern. While cryptographers are currently working on improving tracing apps to address the issue, tracking apps can only be effective when they are used by a significant proportion of the population. Therefore, it is critical that the functionality and safety of these applications are considered acceptable by the majority of the population.  Through the analysis of the data generated from various networks, healthcare organizations can benefit from sensible information, resulting in real-time disease monitoring and control. However, as the use of technology as a means to produce more and more data to drive insights and foresight increases, the ability to automate and analyze that data becomes a necessity. Accelerated digitalization in the healthcare space has revealed gaps in infrastructure, workforce, and digital education that ultimately need to be bridged.   Real World Evidence Solutions Market Dynamics Without intelligent analytics, RWE alone will not be able to produce meaningful and actionable results. Previously, the healthcare industry did not have the ability to gather RWE at the speed and scale needed to address urgent public health crises. However, this scenario has changed due to the pandemic. Advances in analytics and access to broad and diverse real-world data sets have made it possible to rapidly analyze data as it is captured to better understand how pandemics like COVID-19 are unfolding.  The pre-approved use of RWE in efficacy decisions is being carried out currently, and there is potential for it to be used more broadly, such as in oncology, rare diseases, and pediatric conditions when randomized controlled clinical trials are impossible or unethical to conduct. In parallel, legislators are recognizing the value of RWE. In the US, the 21st Century Cures Act, passed in December 2016, has established public-private partnerships to collect data and improve the understanding of diseases. 
Covid-19 Impact and Future Scenario For Medical Ceramics - Research, Future Analysis
The global spread of COVID-19 has led to the complete suspension of elective surgeries, especially in the most affected countries. Some regions witnessed a 70% reduction in the number of patients seeking aesthetic treatments from January 2020 onwards. Moreover, several dental events have been postponed due to the COVID-19 pandemic.  For instance, KRAKDENT 2020, the largest dental show in Poland and an event that attracts over 15,000 visitors worldwide has been rescheduled. The CEO of Straumann Group announced that the COVID-19 outbreak was expected to reduce sales in the Asia Pacific in FY 2020 by at least USD 31 million. Additionally, DENTSPLY Sirona recently predicted that its sales in the Chinese, South Korean, Taiwanese, and Japanese markets would fall by a cumulative USD 60–70 million in FY 2020.   Medical implants are artificial devices that are used to replace damaged or missing biological parts. Implants help deliver medication, monitor body functions, and provide support to organs and tissues in different applications (such as dental, orthopedic, and cardiovascular).   The medical implants market is driven by the growing healthcare needs of the senior population, advancements in medical technologies, and the rising incidence of chronic diseases, such as osteoarthritis, cardiovascular diseases, neuropathic diseases, and congenital disorders, among others.  The significant growth in the geriatric population is expected to result in an increased demand for joint reconstruction, cardiovascular surgeries, and dental replacement procedures and an increase in the prevalence of hearing loss. These factors are, in turn, expected to support the growth of the hearing, orthopedic, and dental implants market.  For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=237425129 Medical ceramics are key components in the manufacturing of various implantable devices, such as orthopedic implants (artificial hips, knee, shoulder, wrists, fracture fixation, and bone grafts), cardiovascular implants (heart valves, pacemakers, catheters, grafts, and stents), dental implants (enamels, fillings, prosthetics, and orthodontics), and hearing implants (cochlear implants).  Considering the growing demand for implantable devices in different segments (such as cardiovascular, dental, and orthopedics), the uptake of medical ceramics is expected to increase in the coming years.  These products have to be implanted inside the human body; they need to be biocompatible and comply with the ISO biocompatibility testing standards. However, it is difficult to anticipate the biocompatibility till the later stages of clinical trials, making companies and investors apprehensive of investing in this market.  Also, regulatory procedures are complicated, restrictive, and depend on the composition of ceramics and their future applications, making the approval process for medical ceramic products cumbersome, expensive, and time-consuming. These factors are expected to hinder the growth of the medical ceramics market to a certain extent.  The World Economic Forum estimates these emerging economies to account for around one-third of the global healthcare expenditure by 2020. The rising geriatric population in these countries will lead to increased demand for medical facilities and devices, which is likely to propel the growth of the medical ceramics market. Moreover, growth in these markets can primarily be attributed to the low prices of dental treatments in these countries compared to developed economies and their infrastructural development.   Additionally, medical device manufacturers are also setting up their facilities in the Asia Pacific, the Middle East, and Latin America. In recent years, key players such as Baxter International, Becton Dickinson, BIOTRONIK, Hoya Surgical Optics, Life Technologies, Medtronic, Siemens Medical Instruments, and AB SCIEX have set up their manufacturing and RD facilities in Singapore.  The lack of a skilled workforce and proper techniques to repair further highlight the issue of reparability. Medical ceramics have a long lifespan but are not recyclable. Due to the long lifespan and various mechanical and optical properties of medical ceramics, the different composites used in various end-use applications face recyclability and reparability. This is one of the major challenges hampering the growth of the medical ceramics market.  The medical ceramics market in Asia Pacific, particularly in China, Japan, and India, is expected to witness high growth in the coming five years. The medical ceramics market in the APAC is estimated to grow rapidly during the forecast period, considering the development of the region's healthcare sector. The major consumers of medical ceramics in the APAC are China, South Korea, and Japan.